Key Stats for Pfizer Stock
- 52-Week Range: $23 to $29
- Current Price: $26
- Street Mean Target: $29
- Street High Target: $36
- Analyst Consensus: 9 Buys / 2 Outperforms / 15 Holds / 2 Underperforms / 1 Sell
- TIKR Model Target (Dec. 2030): $29
Pfizer Stock Posts a Q1 Revenue Beat as the Post-2028 Growth Story Takes Shape
Pfizer Inc. (PFE), one of the world’s largest pharmaceutical companies with an approximately $145 billion market cap, delivered a Q1 2026 revenue beat and reaffirmed full-year guidance following its May 5 earnings call, with Pfizer stock trading near $25.66 as of May 19.
Total revenue for Q1 came in at $14.45 billion, topping consensus estimates of $13.79 billion, driven by strong demand for blood thinner Eliquis and 22% operational growth from launched and acquired products.
Adjusted diluted EPS of $0.75 beat the $0.72 consensus estimate by 3 cents, even as reported EPS fell 10% year-over-year to $0.47 on lower COVID-related product sales.
The most consequential development of the quarter was not the earnings beat itself but the legal clarity that came with it: Pfizer settled patent disputes with Dexcel, Hikma, and Cipla over Vyndamax, extending U.S. patent protection to June 1, 2031 and pushing out a previously feared 2029 revenue cliff.
CEO Albert Bourla said on the Q1 2026 earnings call: “Our recent settlement agreements resolving infringement of patents related to Vyndamax have the potential to change the growth profile of the company significantly post-2028.”
The Vyndamax settlement alone removes roughly $2 billion to $3 billion in annual risk from Pfizer’s late-decade earnings model, and combined with a Belgian court ruling requiring Poland and Romania to honor 1.9 billion euros in COVID-vaccine contracts, it underpins management’s confidence in a high single-digit five-year revenue CAGR beginning in 2029.
Beyond legal wins, Pfizer’s Q1 oncology portfolio showed genuine commercial momentum, with Seagen products delivering 20% operational revenue growth and newly acquired Padcev contributing meaningfully alongside Nurtec, which grew 41% operationally on strong demand for migraine treatment.
Wall Street Holds Its Ground on Pfizer Stock Despite Legal Wins and an Earnings Beat
Nine analysts currently rate Pfizer stock a Buy, two rate it Outperform, 15 rate it Hold, two rate it Underperform, and one rates it a Sell, with a Wall Street mean price target of around $29 against a current price of $25.66, implying roughly 13% upside.
That “Hold”-heavy distribution is not skepticism about Pfizer’s fundamentals — it reflects a structural reality: the company faces sequential LOE headwinds through 2028, and the market is waiting for pipeline catalysts to derisk the back half of the decade before rewarding the stock with a meaningful re-rating.
The thesis here is not about what Pfizer earns next quarter. The story is whether the combination of launched products, legal settlements, and pipeline readouts can bridge the LOE gap cleanly enough that the 2029 inflection point becomes inevitable rather than aspirational.
On the metric that matters most for this type of story — EPS — consensus estimates show $0.68 for Q2 2026 (down around 13% year-over-year), $0.85 for Q3 (down around 3%), and $0.69 for Q4 (up around 5%), before recovering toward $0.63 in early 2027, reflecting the ongoing drag from Comirnaty and Paxlovid declines.
The full-year 2026 adjusted EPS guidance of $2.80 to $3.00 was reaffirmed on the call, and CFO David Denton noted the Q1 outperformance would likely have prompted a raise if not for COVID seasonality weighting toward H2.
The bullish read: launched and acquired products are already running at an annualized pace above $12 billion, Vyndamax now has runway through mid-2031 (versus an earlier cliff in 2029), and the Metsera obesity pipeline targets a first approval in 2028 in a market some analysts see exceeding $100 billion annually.
The bear read: revenue is still declining on a year-over-year basis across most forward quarters, EPS compression continues through 2027, and the $7 billion in BD capacity has not yet been deployed toward anything that materially accelerates the timeline.
Pfizer’s $35 Mid-Case Hinges on a Multiple That Has Not Re-Rated Yet
TIKR’s mid-case values Pfizer at around $28 per share by December 2030, assuming around negative 1% revenue CAGR through the forecast period, a net income margin of roughly 25%, and modestly improving P/E multiple assumptions — implying a total return of around 38% and an annualized IRR of around 4% from current levels.
The range of outcomes is wide.
At around $30 in the low case and around $40 in the high case by the end of 2034, Pfizer stock is undervalued at $25.66, particularly given that the Vyndamax settlement and Belgian court ruling materially de-risk the cash flow bridge into the high-growth period Bourla has committed to post-2028.
Is Pfizer stock undervalued right now?
TIKR’s mid-case model values Pfizer at around $28 per share by the end of 2030, implying around 38% total return from current levels.
With 9 Buy ratings, 2 Outperforms, and a Wall Street mean target of around $29, the stock appears undervalued on a multi-year basis, with the Vyndamax settlement and post-2028 high single-digit CAGR commitment as the primary re-rating catalysts.
The key variable is execution on the obesity and oncology pipeline through 2028.
Should You Invest in Pfizer Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze PFE stock on TIKR for Free →
